What is the current valuation multiple (e.g., P/E, EV/EBITDA) after this earnings release and how does it compare to peers?

Answer

Below is a step‑by‑step explanation of what we can (and cannot) determine about Limbic Holdings, Inc.’s (NASDAQ: LMB) valuation multiples from the information you supplied, together with a practical framework for calculating the multiples and a quick look at how they usually compare to peers in the specialty chemicals / industrial services space.

1. What the press release tells us

These figures are quarterly. To get an annualized view we typically:

• Annualize revenue → $142.2 M × 4 = $568.8 M (or use the trailing twelve‑month (TTM) figure if the company reports a full‑year prior to the quarter).
• Annualize net income → $7.8 M × 4 = $31.2 M.
• Annualize adjusted net income → $11.3 M × 4 = $45.2 M.

Note: The press release does not provide the current share price, market‑capitalisation, total debt, cash, or any other balance‑sheet items needed to compute valuation multiples such as P/E, EV/EBITDA, EV/EBIT, etc. Consequently, we cannot give you a precise “current valuation multiple” from this release alone.

2. How to calculate the most common multiples

Typical sources for the missing pieces

Example (illustrative only – NOT based on real LMB data)

Assume (for illustration) that on August 13 2025 LMB trades at $30 per share and has 30 million diluted shares outstanding (typical for a $142 M‑revenue company). Then:

• Annual EPS = $7.8 M ÷ 30 M = $0.26 per share → P/E = $30 ÷ $0.26 ≈ 115×.
  
• Adjusted EPS = $11.3 M ÷ 30 M = $0.38 per share → P/Adj‑E ≈ 79×.
  

If the balance sheet shows $50 M of total debt, $10 M of cash, and $5 M of capital‑lease liabilities, then:

• EV = Market‑cap ($30 × 30 M = $900 M) + Debt $50 M – Cash $10 M + Lease $5 M ≈ $945 M.
  
• EBITDA (using adjusted net income as a proxy for EBITDA in many specialty‑chemical firms) ≈ $45 M (annualized adjusted net income).
  
• EV/EBITDA = $945 M ÷ $45 M ≈ 21×.

These numbers are purely illustrative; you would need the actual market data to replace the placeholders.

3. How Limbic’s multiples typically compare to peers

Peer group definition

For a specialty‑chemical / industrial‑services company like Limbic, analysts usually compare against:

(Exact numbers vary; the point is to pick publicly‑traded firms with similar revenue size, margins, and geographic exposure.)

Typical valuation ranges (FY2024‑FY2025)

Interpretation

• If Limbic’s actual P/E or EV/EBITDA is in the 20‑30× range, it would still be in line with many specialty‑chemical peers, which often trade at 15‑25× EV/EBITDA because of stable cash flows and modest growth expectations.
• If the multiples are > 30×, the market is pricing Limbic at a premium—perhaps reflecting expectations of continued high‑growth (16 % YoY revenue growth) or a strategic acquisition pipeline that isn’t yet reflected in the balance sheet.
• Conversely, if the multiples are < 10×, the stock could be undervalued relative to peers, suggesting the market may be under‑appreciating the recent earnings acceleration.

4. What to do next – Getting the exact numbers

1. Grab the latest share price (e.g., via Nasdaq.com, Yahoo Finance, or your brokerage platform).
   
2. Find the diluted share count – usually listed on the “Key Statistics” page of the same source or in the company’s most recent 10‑Q.
   
3. Pull the balance‑sheet totals (total debt, cash, lease liabilities) from the 10‑Q filed for the quarter ended 30 June 2025.
   
4. Calculate:
   • P/E = Share price ÷ (Net income ÷ Shares).
     
   • EV/EBITDA = (Market‑cap + Debt – Cash + Lease) ÷ (EBITDA).
     
5. Benchmark against the peer multiples you can obtain from a data‑provider (e.g., Bloomberg’s “Relative Valuation” screen) or by manually pulling the same data for the three or four comparable specialty‑chemical firms listed above.

5. Bottom line

• The press release alone does not provide enough data to compute Limbic’s current valuation multiples.
  
• You can calculate them once you have the current share price, shares outstanding, and balance‑sheet items (debt, cash, lease liabilities).
  
• When you do the math, compare the resulting P/E and EV/EBITDA to the typical peer ranges (≈ 15‑25× EV/EBITDA, ≈ 18‑22× P/E for mid‑cap specialty‑chemical peers).
  
• If Limbic’s multiples are materially higher, the market is rewarding the recent acceleration in revenue and margins; if they are lower, the stock may be undervalued relative to its peers.

Quick checklist for you

Once you fill in those data points, plug them into the formulas above and you’ll have a precise, comparable valuation multiple for Limbic Holdings after its Q2 2025 earnings release. If you need help locating any of those filings or interpreting the balance‑sheet line items, feel free to let me know!